Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

By J. Beizer. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2005

755 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/af024b0c7e95d92a31dc1d3da00b748cdab11890

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Yancy
2. B. Bozkurt
3. M. Gheorghiade
4. M. Jessup
5. G. Fonarow
6. A. Ambrosy
7. J. Butler
8. D. Casey

Citations in the corpus

• 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “The major risk associated with use of aldosterone receptor antagonists is hyperkalemia due to inhibition of potassium excretion, ranging from 2% to 5% in large clinical trials(425,426,446) to 24% to 36% in population-based registries.(479,480) Routine triple combination of an ACE inhibitor, ARB, and”
• Randomized trials stopped early for benefit: a systematic review. (2005, unknown): “Other boundaries/ spending functions 13 (9)”
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “The major risk associated with use of aldosterone receptor antagonists is hyperkalemia due to inhibition of potassium excretion, ranging from 2% to 5% in large clinical trials (425,426,446) to 24% to 36% in population-based registries (479,480).”
• Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence (2014, background): “The observational data demonstrated that uptake of spironolactone in the real world was associated with increased morbidity and mortality due to hyperkalaemia and no improvement in rates of readmission to hospital for heart failure or overall survival (Juurlink et al, 2004).”
• Cardiorenal syndrome. (2008, unknown): “…the use of aldosterone blockade, particularly in conjunction with angiotensin blockade, since after publication of RALES (Randomized Aldactone Evaluation Study) (146), prescriptions for spirono-lactone and rates of hospitalizations and mortality related to hyperkalemia increased sharply (147).”
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡ (2008, unknown): “concentration; if either is used, serial monitoring of serum electrolytes and renal function is mandatory.(110) † Spironolactone can also cause breast discomfort and enlargement in men (10% compared with placebo, in RALES); this side effect is infrequent with eplerenone.”
• Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. (2009, methodology): “These databases have been used in numerous large-scale epidemiologic studies.(19,20) Hospitalization records were obtained from the Canadian Institute for Heath Information Discharge Abstract Database (DAD), which was used to identify an acute hospitalization, the presence of acute kidney injury, an”
• The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. (2014, background): “Although the indication for MRAs has recently been expanded to include HFrEF patients spanning from mild to severe symptoms (55), providers may still be reluctant to prescribe these medications due to the risk of hyperkalemia and arrhythmic events (56).”